Kyowa Kirin’s Poteligeo provides progression-free survival in CTCL trial
Kyowa Kirin has reported that the MAVORIC trial of Poteligeo (mogamulizumab) in patients with mycosis fungoides (MF) and Sézary syndrome…

Kyowa Kirin has reported that the MAVORIC trial of Poteligeo (mogamulizumab) in patients with mycosis fungoides (MF) and Sézary syndrome…
The UK confirmed its first 2019-nCoV (now COVID-19) infection case, following France and Germany, on 31 January 2020 and has…